This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Cyclacel Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
We currently do not have sufficient information about the CEO.
Informazioni chiave
Spiro Rombotis
Amministratore delegato
US$661.0k
Compenso totale
| Percentuale dello stipendio del CEO | 84.7% |
| Mandato del CEO | 26.6yrs |
| Proprietà del CEO | 2.2% |
| Durata media del management | Nessun dato |
| Durata media del Consiglio di amministrazione | 7.5yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$764k | US$546k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$20m |
| Dec 31 2021 | US$1m | US$531k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$1m | US$531k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$1m | US$531k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$8m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$753k | US$531k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$776k | US$531k | -US$15m |
Compensazione vs Mercato: Spiro's total compensation ($USD661.05K) is above average for companies of similar size in the German market ($USD404.23K).
Compensazione vs guadagni: Spiro's compensation has been consistent with company performance over the past year.
AMMINISTRATORE DELEGATO
Spiro Rombotis (64 yo)
26.6yrs
Mandato
US$661,049
Compensazione
Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 18yrs | US$661.05k | 2.19% $ 64.5k | |
| Executive VP of Finance | 18yrs | US$352.62k | 1.19% $ 35.0k | |
| Chief Medical Officer & Director | 3.3yrs | US$101.00k | 0.096% $ 2.8k | |
| Independent Director | 9.5yrs | US$116.50k | 0.32% $ 9.3k | |
| Independent Chairman | 18yrs | US$155.50k | 0.31% $ 9.1k | |
| Independent Director | 3.3yrs | US$95.49k | 0.32% $ 9.3k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Vice Chairman | 5.5yrs | US$130.75k | 0.31% $ 9.1k | |
| Independent Director | 1.8yrs | US$85.49k | 0.17% $ 4.9k |
7.5yrs
Durata media
67yo
Età media
Consiglio di amministrazione esperto: UXI's board of directors are considered experienced (7.5 years average tenure).